Asian Spectator


The Times

.

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

  • Written by ACN Newswire - Press Releases
SHANGHAI, CHINA, Dec 18, 2020 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced:

Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial

- Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of...

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink jojobetStreamEastStreamEasthitbet girişroyalbetjojobetjojobetcasino siteleriPadişahbetPadişahbetDizipalStreamEastPadişahbetGalabetmarsbahisjojobetjojobetcasibomhttps://chantilly-montessori-school.vercel.app/esim senegalbetparkbetparktelegram下载jojobetcasibomholiganbetatlasbetatlasbetatlasbetjojobetjojobet